{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:20:06Z","timestamp":1784704806570,"version":"3.55.0"},"reference-count":11,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Objective: To review trials evaluating the efficacy and safety of Vaxchora, a reformulated, single-dose, oral, lyophilized Vibrio cholerae CVD 103-HgR vaccine for the prevention of travel-related cholera caused by V cholerae serogroup O1. Data Sources: A literature search was conducted using MEDLINE (1946 to January week 3, 2017) and EMBASE (1996 to 2017 week 3). Keywords included oral cholera vaccine, single-dose, Vaxchora, and CVD 103-HgR. Limits included human, clinical trials published in English since 2010. ClinicalTrials.gov was used as a source for unpublished data. Additional data sources were obtained through bibliographic review of selected articles. Study Selection and Data Extraction: Studies that addressed the safety and efficacy of Vaxchora, the reformulated, single-dose oral CVD 103-HgR cholera vaccine, were selected for analysis. Data Synthesis: Approval of Vaxchora, was based on efficacy of the vaccine in human trials demonstrating 90.3% protection among those challenged with V cholerae 10 days after vaccination and in immunogenicity studies with 90% systemic vibriocidal antibody conversion at 6 months after a single-dose of vaccine. Tolerability was acceptable, with the most common adverse effects reported to be fatigue, headache, and abdominal pain. Conclusion: Vaxchora is the only FDA-approved, single-dose oral vaccine for the prevention of cholera caused by V cholerae serogroup O1 in adult travelers from the United States going to cholera-affected areas. Safety and efficacy has not been established in children, immunocompromised persons, and pregnant or breastfeeding women or those living in cholera-endemic areas.<\/jats:p>","DOI":"10.1177\/1060028017698162","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T05:07:01Z","timestamp":1488949621000},"page":"584-589","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Vaxchora: A Single-Dose Oral Cholera Vaccine"],"prefix":"10.1177","volume":"51","author":[{"given":"Adriana","family":"Cabrera","sequence":"first","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne E.","family":"Lepage","sequence":"additional","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyn M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila M.","family":"Seed","sequence":"additional","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"bibr6-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00601-13."},{"key":"bibr8-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2016.07.003."},{"key":"bibr10-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199907000-00011"},{"key":"bibr11-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.60.10.4430-4432.1992"},{"key":"bibr12-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.12.6341-6345.1999"},{"key":"bibr13-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92231-4"},{"key":"bibr14-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw145."},{"key":"bibr18-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.61.9.3994-3997.1993"},{"key":"bibr19-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-8-129."},{"key":"bibr20-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92231-4"},{"key":"bibr21-1060028017698162","doi-asserted-by":"publisher","DOI":"10.1086\/513984"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017698162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028017698162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017698162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:52Z","timestamp":1777375012000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028017698162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1177\/1060028017698162"],"URL":"https:\/\/doi.org\/10.1177\/1060028017698162","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}